In spite of preclinical evidence showing a predictive role of specific genetic aberrations in the PI3K/AKT/mTOR pathway [14, 15], clinical data failed to confirm the correlation between a specific mutation status in the primary BC tissue and sensitivity/resistance to everolimus. This evidence concerns the gene AKT1 and breast cancer.